[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,405
  • Shares Outstanding, K 41,032
  • Annual Sales, $ 1,270 K
  • Annual Income, $ -69,690 K
  • EBIT $ -72 M
  • EBITDA $ -72 M
  • 60-Month Beta 0.40
  • Price/Sales 7.76
  • Price/Cash Flow N/A
  • Price/Book 0.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.83
  • Most Recent Earnings $-0.37 on 06/15/26
  • Next Earnings Date 08/06/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 287.02% (+15.11%)
  • Historical Volatility 359.11%
  • IV Percentile 53%
  • IV Rank 35.04%
  • IV High 682.81% on 07/10/26
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 31) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 107
  • Volume Avg (30-Day) 1,123
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 26,531
  • Open Int (30-Day) 33,313
  • Expected Range 0.2311 to 0.2311

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 2
  • High Estimate $-0.23
  • Low Estimate $-0.35
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) +38.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1980 +16.72%
on 06/30/26
0.7997 -71.10%
on 06/29/26
-0.4391 (-65.52%)
since 06/18/26
3-Month
0.1980 +16.72%
on 06/30/26
0.7997 -71.10%
on 06/29/26
-0.3776 (-62.03%)
since 04/20/26
52-Week
0.1980 +16.72%
on 06/30/26
5.1400 -95.50%
on 11/24/25
-2.3189 (-90.94%)
since 07/18/25

Most Recent Stories

More News
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically...

VTGN : 0.2311 (+0.83%)
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed...

VTGN : 0.2311 (+0.83%)
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

VTGN : 0.2311 (+0.83%)
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

NEW YORK , June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:...

VTGN : 0.2311 (+0.83%)
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

VTGN : 0.2311 (+0.83%)
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Dr. Angelov brings extensive industry experience across multiple therapeutic areas

VTGN : 0.2311 (+0.83%)
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

VTGN : 0.2311 (+0.83%)
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months ...

VTGN : 0.2311 (+0.83%)
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026

VTGN : 0.2311 (+0.83%)
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

SAN FRANCISCO , April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therapeutics, Inc. (NASDAQ: VTGN) investors that the firm is investigating potential legal claims arising...

VTGN : 0.2311 (+0.83%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.2436
2nd Resistance Point 0.2390
1st Resistance Point 0.2351
Last Price 0.2311
1st Support Level 0.2266
2nd Support Level 0.2220
3rd Support Level 0.2181

See More

52-Week High 5.1400
Fibonacci 61.8% 3.2522
Fibonacci 50% 2.6690
Fibonacci 38.2% 2.0858
Last Price 0.2311
52-Week Low 0.1980

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.